Skip to content

Exagen Inc. XGN Free cash flow

Free cash flow at other companies

Vor Biopharma logo
Vor BiopharmaVOR
-$38.29M-22.4%
CareDx logo
CareDxCDNA
$514K+102%
Labcorp Holdings logo
Labcorp HoldingsLH
Quest Diagnostics logo
Quest DiagnosticsDGX
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Revvity logo
RevvityRVTY

Other financials

Income statement

See full
Revenue$17.3M+11.7%
Gross profit$10.2M+11.9%
Operating income-$3.4M-1.5%
Net income-$4.0M-5.7%
EPS (diluted)-$0.17+15.0%

Balance sheet

See full
Cash & equivalents$21.7M+90.6%
Total debt$27.1M+15.8%
Total equity$14.4M+125%
Total assets$52.0M+28.9%

Cash flow

See full
Operating cash flow-$10.4M+2.4%
CapEx$228.0K+102%

Valuation

See full
Market cap$112.34M-26.5%
Enterprise value$117.78M-20.3%
P/S1.6×-1.0×

Profitability

See full
Gross margin58.3%-1.0pp
Operating margin-20.6%-2.9pp
Net margin-29.5%+2.5pp
FCF margin-27.5%

Returns & leverage

See full
Return on equity-193.6%+355pp
Debt / equity1.9×-1.8×
Current ratio3.5×+1.1×

Where this comes from

Calculated from Exagen Inc.’s reported figures.

The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exagen Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exagen Inc.'s free cash flow?
Exagen Inc. (XGN) reported free cash flow of -$10.65M in Q1 2026.
How has Exagen Inc.'s free cash flow changed year-over-year?
Exagen Inc.'s free cash flow increased by 1.3% year-over-year, from -$10.78M to -$10.65M.
What is the long-term trend for Exagen Inc.'s free cash flow?
Over 2 years (2021 to 2024), Exagen Inc.'s free cash flow has grown at a -21.3% compound annual growth rate (CAGR), from -$22.64M to -$14.01M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.